Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Depeng Li

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Journal of Dairy Science|March 7, 2025
Cullin 3 mitigates nonesterified fatty acid-induced oxidative stress in mammary epithelial cells: Involvement of BCL2/BECN1 and autophagyYifei Dong, Wenwen Gao, Kai Liu, et al.
Frontiers in Oncology|July 1, 2021
An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective StudyKunming Qi, Zhiling Yan, Hai Cheng, et al.
Frontiers in Immunology|November 15, 2021
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell TherapyWei Chen, Yuhan Ma, Ziyuan Shen, et al.
BMC Medicine|June 13, 2026
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysisFan Xia, Bin Lv, Xinyi Li, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 11, 2022
Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myelomaDian Zhou, Ying Wang, Hai Cheng, et al.
Frontiers in Immunology|May 2, 2025
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapyLingling Yin, Bin Lv, Jiao Ge, et al.
Frontiers in Immunology|May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cellsYang Liu, Xingxing Jie, Li Nian, et al.
Transplantation and Cellular Therapy|March 30, 2021
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple MyelomaWei Chen, Ying Wang, Kunming Qi, et al.
Cytotherapy|March 12, 2023
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaSha Ma, Hujun Li, Dian Zhou, et al.
American Journal of Hematology|July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ productionWei Sang, Cong Zhang, Dianzheng Zhang, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Journal of Dairy Science|March 7, 2025
Cullin 3 mitigates nonesterified fatty acid-induced oxidative stress in mammary epithelial cells: Involvement of BCL2/BECN1 and autophagyYifei Dong, Wenwen Gao, Kai Liu, et al.
Frontiers in Oncology|July 1, 2021
An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective StudyKunming Qi, Zhiling Yan, Hai Cheng, et al.
Frontiers in Immunology|November 15, 2021
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell TherapyWei Chen, Yuhan Ma, Ziyuan Shen, et al.
BMC Medicine|June 13, 2026
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysisFan Xia, Bin Lv, Xinyi Li, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 11, 2022
Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myelomaDian Zhou, Ying Wang, Hai Cheng, et al.
Frontiers in Immunology|May 2, 2025
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapyLingling Yin, Bin Lv, Jiao Ge, et al.
Frontiers in Immunology|May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cellsYang Liu, Xingxing Jie, Li Nian, et al.
Transplantation and Cellular Therapy|March 30, 2021
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple MyelomaWei Chen, Ying Wang, Kunming Qi, et al.
Cytotherapy|March 12, 2023
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaSha Ma, Hujun Li, Dian Zhou, et al.
American Journal of Hematology|July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ productionWei Sang, Cong Zhang, Dianzheng Zhang, et al.
Pageof 11